Economic evaluation of five first-line PD-(L)1 inhibitors for treating non-squamous non-small cell lung cancer in China: A cost-effectiveness analysis based on network meta-analysis
Background and objective: Non-small cell lung cancer (NSCLC) is one of the most malignant cancer types that causes substantial economic burden in China. This study aimed to evaluate the cost-effectiveness of five first-line anti-PD-(L)1 treatments, including sintilimab, camrelizumab, atezolizumab, p...
Main Authors: | Xi Chen, Mingye Zhao, Lei Tian |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-03-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1119906/full |
Similar Items
-
A systematic review and network meta-analysis of first-line immune checkpoint inhibitor combination therapies in patients with advanced non-squamous non-small cell lung cancer
by: Taihang Shao, et al.
Published: (2022-10-01) -
Identifying optimal PD-1/PD-L1 inhibitors in first-line treatment of patients with advanced squamous non-small cell lung cancer in China: Updated systematic review and network meta-analysis
by: Mingye Zhao, et al.
Published: (2022-09-01) -
Cost-effectiveness of additional serplulimab to chemotherapy in metastatic squamous non-small cell lung cancer patients
by: Hanrui Zheng, et al.
Published: (2024-04-01) -
Effectiveness and cost-effectiveness analysis of 11 treatment paths, seven first-line and three second-line treatments for Chinese patients with advanced wild-type squamous non-small cell lung cancer: A sequential model
by: Mingye Zhao, et al.
Published: (2023-02-01) -
Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50%
by: Qiao Liu, et al.
Published: (2022-01-01)